SCHEMBL6237718

SCHEMBL6237718

CC(C)S(=O)(=O)NC1CCC=C1c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDFT1 P37268 1/20 0.49
ADAMTS4 O75173 3/20 0.46
MMP13 P45452 1/20 0.46
AR P10275 7/20 0.43
NPC1 O15118 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
UCHL1 P09936 1/20 0.41
USP30 Q70CQ3 1/20 0.41
ACACB O00763 1/20 0.40
GSTP1 P09211 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA4 P22748 1/20 0.40
CA5A P35218 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA5B Q9Y2D0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6240540 0.86 ADAM17 (0.41) FDFT1ADAMTS4MMP13AR
SCHEMBL6237723 0.84 AR (0.47) FDFT1ADAMTS4MMP13ARNPC1
SCHEMBL6243805 0.84 GRIA4 (0.44) ADAMTS4MMP13CYP1A2
SCHEMBL6239993 0.82 MMP2 (0.34) MMP13ACACBMEN1KMT2ALTA4H
SCHEMBL6243776 0.81 GRIA2 (0.36) ADAMTS4MMP13
SCHEMBL6242856 0.81 ALDH1A1 (0.37) CA12CA1CA2CA9MEN1
SCHEMBL6240728 0.81 GRIA4 (0.39) FDFT1ADAMTS4MMP13
SCHEMBL6242243 0.79 CXCR2 (0.37) ADAMTS4CYP1A2
SCHEMBL6239568 0.78 ADAMTS4 (0.47) ADAMTS4MMP13KMT2A
SCHEMBL6246315 0.77 GRIA4 (0.45) ADAMTS4MMP13CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1395550-B1 CYCLOALKENYLSULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2005-06-29 EP claimed
US-20040157817-A1 Cycloalkenylsulfonamide derivatives CANTELL BUDDY EUGENE (US) 2004-08-12 US claimed
EP-1395550-A1 CYCLOALKENYLSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2004-03-10 EP claimed
WO-2002098847-A1 CYCLOALKENYLSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-12 WO claimed
EP-1395550-B1 CYCLOALKENYLSULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2005-06-29 EP disclosed
US-20040157817-A1 Cycloalkenylsulfonamide derivatives CANTELL BUDDY EUGENE (US) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157817-A1 Cycloalkenylsulfonamide derivatives GRIN2B, GRIN2A, GRIN1 FDFT1 1106/4885ADAMTS4 3846/4885MMP13 4825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.